Treatment of autism and autism spectrum disorders with biotin compositions

Abstract

The present application relates to the treatment of autism and autism spectrum disorders using biotin compositions.

1 .- 20 . (canceled). 
     
     
         21 . A method for increasing carboxylase serum levels in an individual, the method comprising administering magnesium biotinate to the individual. 
     
     
         22 . The method of  claim 21 , wherein samples are obtained from blood, serum, peripheral blood mononuclear cell (PBMC), saliva, urine, feces or sweat from the individual. 
     
     
         23 . The method of  claim 21 , wherein the magnesium biotinate is administered at least once a day. 
     
     
         24 . The method of  claim 21 , wherein the magnesium biotinate is administered by a route selected from the group consisting of oral, intraperitoneal, transdermal, rectal, and sublingual. 
     
     
         25 . The method of  claim 24 , wherein the magnesium biotinate is administered via an oral route. 
     
     
         26 . The method of  claim 25 , wherein the magnesium biotinate is formulated as a tablet, aqueous or oil suspension, dispersible powder or granule, emulsion, hard or soft capsule, syrup, elixir, or beverage. 
     
     
         27 . The method of  claim 21 , wherein an amount of magnesium biotinate administered is between about 10 mg/day and about 1000 mg/day. 
     
     
         28 . The method of  claim 27 , wherein the amount of magnesium biotinate administered is between about 10 mg/day and about 100 mg/day. 
     
     
         29 . The method of  claim 21 , wherein the magnesium biotinate is provided as a drug, supplement, food, medical food, or biologic. 
     
     
         30 . The method of  claim 21 , wherein the magnesium biotinate is administered alone. 
     
     
         31 . The method of  claim 21 , wherein the magnesium biotinate is administered with another compound. 
     
     
         32 . The method of  claim 21 , wherein the magnesium biotinate is administered for at least one day. 
     
     
         33 . The method of  claim 21 , wherein the magnesium biotinate is administered for at least one week. 
     
     
         34 . The method of  claim 21 , wherein the magnesium biotinate is administered for at least one month. 
     
     
         35 . The method of  claim 21 , wherein the magnesium biotinate is administered to a pregnant woman. 
     
     
         36 . The method of  claim 21 , wherein the individual is a child. 
     
     
         37 . The method of  claim 36 , wherein the child has autism spectrum disorder. 
     
     
         38 . The method of  claim 21 , wherein after the administration of the magnesium biotinate, the intellectual abilities of the individual are improved. 
     
     
         39 . The method of  claim 21 , wherein after the administration of the magnesium biotinate, the non-verbal intellectual abilities of the individual are improved. 
     
     
         40 . The method of  claim 21 , wherein after the administration of magnesium biotinate, the development age of the individual is improved.